REZZAYO
Peakrezafungin
NDAINTRAVENOUSPOWDERPriority Review
Approved
Mar 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REZZAYO (rezafungin) is an intravenous echinocandin antifungal approved in March 2023 for invasive fungal infections. It represents a novel once-weekly dosing option within the echinocandin class, designed to provide convenient treatment for hospitalized patients with serious fungal infections. The mechanism leverages echinocandin class pharmacology to inhibit fungal cell wall synthesis.
$0.061MPart D
Peak11.7 years to LOEEarly commercial traction in a niche fungal infection market; expect focused commercial team supporting hospital/IDN accounts with modest growth trajectory.
Mechanism of Action
Pharmacologic Class:
Echinocandin Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Safety and Pharmacokinetics of Rezafungin
Started Dec 2019
14 enrolled
Fungal Infection
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
Started Oct 2018
199 enrolled
CandidemiaMycosesFungal Infection+1 more
Career Relevance
Working on REZZAYO offers early-stage brand ownership in a niche, high-acuity therapeutic area with modest but stable patient volume. The 12-year patent runway provides career stability, though the product's small scale (20 Part D claims in 2023) limits team size and advancement opportunities compared to blockbuster franchises.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.